A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma

被引：3

作者：

Ramachandran, Indu R. ^{[1
]}

Lin, Cindy ^{[1
]}

Chase, Tess ^{[2
]}

Gabrilovich, Dmitry ^{[1
]}

Nefedova, Yulia ^{[1
]}

机构：

[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.5729.5729

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Role of neurotrophin-trk interactions in oncology: The anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models
Ruggeri, BA
Miknyoczki, SJ
Singh, J
Hudkins, RL
CURRENT MEDICINAL CHEMISTRY, 1999, 6 (09) : 845 - 857
[32] Pre-clinical evidence for an anti-tumor activity of defibrotide, a DNA based, endothelium stabilizing drug
Echart, C.
Iacobelli, M.
Richardson, P.
Mitsiades, C.
Ignoni, T.
Ferro, L.
Eissner, G.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[33] Anti-tumor activity of a novel immunosuppressant FTY720 in multiple myeloma.
Yasui, H
Hideshima, T
Roccaro, AM
Shiraishi, N
Hamasaki, M
Ishitsuka, K
Kumar, S
Raje, N
Li, GL
Tai, YT
Podar, K
Chauhan, D
Anderson, KC
BLOOD, 2004, 104 (11) : 941A - 942A
[34] AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics
Wilson, William Casey
Richards, John
Puro, Robyn J.
Andrejeva, Gabriela
Capoccia, Ben J.
Donio, Mike J.
Hiebsch, Ronald R.
Chakraborty, Prabir
Sung, Victoria
Pereira, Daniel S.
BLOOD, 2020, 136
[35] Novel colchicine derivative CR42-24 demonstrates potent anti-tumor activity in urothelial carcinoma
Bell, Clayton J.
Potts, Kyle G.
Hitt, Mary M.
Pink, Desmond
Tuszynski, Jack A.
Lewis, John D.
CANCER LETTERS, 2022, 526 : 168 - 179
[36] The Anti-Tumor Effect of Motesanib in Pre-Clinical Models of Human Basal-Like Breast Cancer
Price, J. E.
Alvarez, R. H.
Xu, C.
Polverino, A.
Radinsky, R.
Coxon, A.
Saffran, D.
CANCER RESEARCH, 2009, 69 (24) : 784S - 784S
[37] AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models
Zhang, Nancy
Caenepeel, Sean
Wang, Ling
Norman, Mark
Kendall, Richard
Burgess, Terri
Radinsky, Robert
Hughes, Paul
Freeman, Daniel J.
CANCER RESEARCH, 2012, 72
[38] Dual targeting of HER3 and PIK3CA has potent anti-tumor effects in pre-clinical models of HNSCC
Khan, Nayel
Davis, Kara S.
Godse, Neal
Kemp, Carolyn
Kulkarni, Sucheta
Alvarado, Diego
LaVallee, Theresa
Grandis, Jennifer R.
Duvvuri, Umamaheswar
CANCER RESEARCH, 2016, 76
[39] A novel and potent Cblb inhibitor demonstrates robust immunological profile and anti-tumor efficacy
Chinnapattu, Murugan
Shelke, Sandeep
Ingale, Prashant
Waghmare, Nayan
Kadlag, Nanasaheb
Pawar, Manoj
Kangane, Akshay
Chaudhari, Sachin S.
Saini, Jagmohan
Kattige, Vidya
Joshi, Arti
Dutta, Colina
Boral, Debjyoti
Kadam, Sheetal
Potdar, Varada
Mani, Jiju
Sawant, Pooja
Marathe, Megha
Mulay, Madhavi
Virdikar, Akshata
Mandadi, Sravan
Akarte, Atul
Singh, Anuj
Misra, Chandrasekhar
Lambade, Pandurang
Tirumalasetty, Chaitanya
Patole, Raju
Karande, Vikas
Behera, Dayanidhi
Jain, Pankaj
Kurawattimath, Vishwanath
Gowda, Nagaraj
Iyer, Pravin S.
CANCER RESEARCH, 2023, 83 (07)
[40] Dendritic cell myeloma fusions stimulate anti-tumor immunity: Results from pre-clinical studies and a clinical trial.
Avigan, D
Vasir, B
Wu, ZI
Uhl, L
Desliva, T
Rosenblatt, J
Levine, JD
Joyce, R
Miller, K
Munshi, N
Richardson, P
Proper, J
Gillombardo, N
Forino, P
Villaroel, M
Anderson, K
Kufe, D
BLOOD, 2004, 104 (11) : 215A - 215A

← 1 2 3 4 5 →